Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant gemcitabine versus observation after curative-intent resection of pancreatic cancer
ISRCTN34802808Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 1998
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in pancreatic cancer (PC) comparing Adjuvant gemcitabine with Observation (2 arms). Primary endpoint: Disease-free survival. Started Jul 1998; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ISRCTN34802808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN34802808.